Your session is about to expire
← Back to Search
Tacrolimus for Hereditary Hemorrhagic Telangiectasia
Study Summary
This trial will investigate whether tacrolimus can reduce epistaxis severity in HHT subjects. If successful, the drug could be used to treat HHT patients with recurrent nosebleeds.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 18 years.I have been diagnosed with HHT either through clinical evaluation or genetic testing.I have no known allergies or reactions to the study drug.I currently have an infection.Your heart's electrical activity is not normal and the QTc measurement is greater than 480msec.I am not pregnant, breastfeeding, nor planning to become pregnant during the study.I am a man and my partner can have children but we are not using effective birth control.Your creatinine levels are higher than the normal range.You are allergic to the study drug or similar medications.My liver enzymes are twice as high as the normal limit.Your BHCG level is below 6 IUL (if it's 6-24 IUL, it will be tested again).I have nosebleeds lasting 15 minutes or more each week.You have at least one visible blood vessel (on the skin or inside the body) that can be examined with a special camera.
- Group 1: Tacrolimus immediate-release capsules
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other research is available regarding the use of low-dosage Tacrolimus capsule?
"At present, 150 clinical studies are in progress to assess the efficacy of Tacrolimus capsule (low-dose), with 18 trials reaching Phase 3. Most research sites for this medication are located in Nashville, Tennessee; however across 871 locations there is currently ongoing testing for Tacrolimus capsule (low-dose)."
How is Tacrolimus capsule (low-dose) usually employed therapeutically?
"The tacrolimus capsule (low-dose) is most often utilized to help patients with dermatitis and atopic conditions. Additionally, it may be beneficial in addressing liver or kidney transplant rejection as well as psoriasis."
Are participants still being welcomed to join this experiment?
"Clinicaltrials.gov attests that this medical trial is still enrolling patients, with its initial posting having been on October 20th 2020 and the most recent edit to the page being from November 10th 2022."
What potential risks accompany ingestion of low-dose Tacrolimus capsules?
"Although limited clinical data exists attesting to the efficacy of tacrolimus capsules (low-dose), there is some evidence that it can be safe, resulting in a safety rating of 2."
How many participants are currently enrolled in this experiment?
"Affirmative. As indicated by clinicaltrials.gov, this trial is actively recruiting patients since its launch on October 20th 2020 and most recent update occurring November 10th 2022. 30 individuals are being sought after across 1 location."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger